Adipocyte-selective reduction of the leptin receptors induced by antisense RNA leads to increased adiposity, dyslipidemia, and insulin resistance
- PMID: 12925533
- DOI: 10.1074/jbc.M304165200
Adipocyte-selective reduction of the leptin receptors induced by antisense RNA leads to increased adiposity, dyslipidemia, and insulin resistance
Abstract
Although recent evidence suggests that leptin can directly regulate a wide spectrum of peripheral functions, including fat metabolism, genetic examples are still needed to illustrate the physiological significance of direct actions of leptin in a given peripheral tissue. To this end, we used a technical knock-out approach to reduce the expression of leptin receptors specifically in white adipose tissue. The evaluation of leptin receptor reduction in adipocytes was based on real time PCR analysis of the mRNA levels, Western blot analysis of the proteins, and biochemical analysis of leptin signaling capability. Despite a normal level of leptin receptors in the hypothalamus and normal food intake, mutant mice developed increased adiposity, decreased body temperature, hyperinsulinemia, hypertriglyceridemia, impaired glucose tolerance and insulin sensitivity, as well as elevated hepatic and skeletal muscle triglyceride levels. In addition, a variety of genes involved in regulating fat and glucose metabolism were dysregulated in white adipose tissue. These include tumor necrosis factor-alpha, adiponectin, leptin, fatty acid synthase, sterol regulatory element-binding protein 1, glycerol kinase, and beta3-adrenergic receptor. Furthermore, the mutant mice are significantly more sensitive to high fat feeding with regard to developing obesity and severe insulin resistance. Thus, we provide a genetic model demonstrating the physiological importance of a peripheral effect of leptin in vivo. Importantly, this suggests the possibility that leptin resistance at the adipocyte level might be a molecular link between obesity and type 2 diabetes.
Similar articles
-
The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice.J Biol Chem. 2006 Apr 21;281(16):11039-49. doi: 10.1074/jbc.M510258200. Epub 2006 Jan 30. J Biol Chem. 2006. PMID: 16446356
-
Estrogen regulation of adiposity and fuel partitioning. Evidence of genomic and non-genomic regulation of lipogenic and oxidative pathways.J Biol Chem. 2005 Oct 28;280(43):35983-91. doi: 10.1074/jbc.M507339200. Epub 2005 Aug 17. J Biol Chem. 2005. PMID: 16109719
-
Targeting the ERK signaling pathway as a potential treatment for insulin resistance and type 2 diabetes.Am J Physiol Endocrinol Metab. 2016 Apr 15;310(8):E643-E651. doi: 10.1152/ajpendo.00445.2015. Epub 2016 Feb 9. Am J Physiol Endocrinol Metab. 2016. PMID: 26860984
-
[Insulin resistance, role of leptin and leptin receptor].Nihon Rinsho. 2000 Feb;58(2):327-32. Nihon Rinsho. 2000. PMID: 10707553 Review. Japanese.
-
The role of adipokines as regulators of skeletal muscle fatty acid metabolism and insulin sensitivity.Acta Physiol (Oxf). 2006 Jan;186(1):5-16. doi: 10.1111/j.1748-1716.2005.01502.x. Acta Physiol (Oxf). 2006. PMID: 16497175 Review.
Cited by
-
Differential effects of leptin on adiponectin expression with weight gain versus obesity.Int J Obes (Lond). 2016 Feb;40(2):266-74. doi: 10.1038/ijo.2015.181. Epub 2015 Sep 16. Int J Obes (Lond). 2016. PMID: 26374448 Free PMC article. Clinical Trial.
-
Tissue-Specific Effects of Leptin on Glucose and Lipid Metabolism.Endocr Rev. 2021 Jan 28;42(1):1-28. doi: 10.1210/endrev/bnaa027. Endocr Rev. 2021. PMID: 33150398 Free PMC article. Review.
-
Sarcopenia and cachexia: molecular mechanisms and therapeutic interventions.MedComm (2020). 2025 Jan 5;6(1):e70030. doi: 10.1002/mco2.70030. eCollection 2025 Jan. MedComm (2020). 2025. PMID: 39764565 Free PMC article. Review.
-
Genome-wide association study identifies polymorphisms in LEPR as determinants of plasma soluble leptin receptor levels.Hum Mol Genet. 2010 May 1;19(9):1846-55. doi: 10.1093/hmg/ddq056. Epub 2010 Feb 17. Hum Mol Genet. 2010. PMID: 20167575 Free PMC article.
-
Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor.Front Endocrinol (Lausanne). 2023 Jun 29;14:1141029. doi: 10.3389/fendo.2023.1141029. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37455900 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials